Antibody sample packs are designed to be cost effective and help you choose which of our many antibodies might work best for your particular sample type or application. This antibody sample pack includes a set of related GPCR polyclonal antibodies for pain research.
The cannabinoid receptors CB1 and CB2 are GPCRs named for their signaling function in response to cannabinoid drugs such as Delta9-tetrahydrocannabinol (Delta9-THC). In addition to Delta9-THC and its synthetic analogs, CB1 and CB2 receptors are bound by endogenous eicosanoid ligands (e.g. anandamide), and signal via Gi/o alpha subunits to regulate adenylyl cyclase activity (generally inhibitory), ion channel activation, intracellular Ca2+ levels, nitric oxide synthase activation, and immediate early gene expression. CB1 and CB2 signals in turn regulate neurological and immunological functions such as inhibition of neurotransmitter release and immune cell migration, antigen processing, and cytokine production.The opioid receptors delta (DOP, OP1), kappa (KOP, OP2), and mu (MOP, OP3) are GPCRs that share ~60% identity, but vary greatly in the extracellular N-terminus region of the receptors. The delta, kappa and mu-receptors serve as functional receptors for endogenous enkephalin, dynorphin, and beta-endorphin peptide ligands, respectively. Delta-opioid receptors function to inhibit neurotransmitter release resulting in a variety of biological effects including analgesia, motor integration, gastro-intestinal motility, olfaction, respiration, and memory. Kappa-opioid receptors are found in the cerebral cortex, nucleus accumbens, claustrum, and hypothalamus, and are known to regulate nociception, diuresis, feeding, as well as immune and neuroendocrine function. The mu-receptor typically functions as a depressant in physiological processes including respiration, cardiovascular function, gastrointestinal motility, and thermoregulation.